TITLE:
Complications of Ziv-Aflibercept in Choroidal and Retinal Vascular Diseases
AUTHORS:
Hussain Ahmad Khaqan, Usman Imtiaz, Laraib Hassan, Sabah Eric, Hasnain Muhammad Bukhsh, Hafiz Mubashir Farooqui, Ahmad Fauzan, Muhammad Usman Zia
KEYWORDS:
Ziv-Aflibercept, Anti VEGF, Choroidal Vascular Diseases, Retinal Vascular Diseases
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.13 No.2,
May
11,
2023
ABSTRACT: Introduction: The modern ophthalmology trends are changing rapidly every day with the introduction of much newer studies and research. Numerous anti-vascular endothelial growth factors (VEGF) are utilized as the mainstay in the treatment of intraocular vascular pathologies. The rationale of this study is to add to the literature regarding the safety and efficacy profile of the ziv-aflibercept as there is insubstantial data in patients with intraocular vascular pathologies being treated with this injection with prime focus on the complications of the injection. Materials and Methods: A prospective observational study was conducted at Opthalmology Department, Lahore General Hospital, Lahore between 14 August 2018 and 23 December 2019. Patients with choroidal and retinal vascular diseases like diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO) who had no active infection of eye and had no history of myocardial infarction or cerebrovascular accident were added in this study. Results: Best-corrected visual acuity was significantly improved at 4, 8, and 12 weeks as compared to the baseline (p Conclusion: The use of ziv-aflibercept injection via intravitreal route under aseptic conditions for choroidal and retinal vascular diseases is effective as well as safe with mild and treatable ocular side effects.